A staged research programme investigating whether minimally invasive biochemical sensing can complement the physiological data wearable devices already capture — beginning with glucose, lactate, sodium, potassium and pH.
The research question
Interstitial fluid sits just beneath the skin and carries many of the same biochemical markers found in blood, with the potential for far less invasive, more continuous access than a blood draw.
Electrochemical methods can detect specific molecules with high sensitivity, at low power and small physical scale — properties that matter for anything intended to be worn continuously.
Wearables already track movement, heart rate and other physiological signals well. Adding a biochemical stream could, if validated, give a fuller picture of the body’s state over time.
Conceptual architecture
A conceptual signal path, not an engineering blueprint of a finished device — each stage below still needs to be researched, built and validated.
Three-stage roadmap
Each stage exists to answer a specific question before committing to the next. Cancer-associated biomarker research is treated as a long-term direction only, contingent on what the science supports at each stage.
Stage 1
Demonstrate trustworthy electrochemical biochemical measurement on the bench.
Stage 2
Move from bench chemistry toward a wearable biochemical interface.
Stage 3
Miniaturize and integrate validated subsystems into a reusable wearable.
At the end of Stage 3, the programme is intended to be positioned to build and verify its first fully integrated wearable prototype — not a market-ready or clinically approved product.
Why validation matters
Biochemical sensing only becomes useful if the measurement itself can be trusted — repeatable, selective for the molecule of interest, stable across temperature and time, and resistant to interference. That is the entire purpose of Stage 1.
More complex, disease-associated biomarker research — including any future investigation of cancer-associated markers — is a long-term direction only. It is not a current capability, and it would only be pursued once the underlying analytical and biosensing science supports it.
Clarity matters
Research status
The Continuous Molecular Health Initiative is an early-stage research programme. It is not a medical device, is not clinically validated, and is not approved to diagnose, screen for, treat or prevent any disease, including cancer.
Support the research
The three-stage roadmap above doubles as a sponsorship and collaboration structure — see how research collaboration, equipment sponsorship and laboratory partnerships map onto each stage.